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Background: Health-related quality of life is a crucial outcome for the chronic kidney disease population, the
Kidney Disease Quality of Life (KDQOL) questionnaire is commonly used as an integral part of clinical evaluations.
The abbreviated version of the KDQOL-36™ has been translated into Mandarin Chinese, but has not been tested for
use in the Chinese patients. The aim of the study was to evaluate the validity and reliability of the KDQOL-36™ with
a sample of Chinese patients.
Methods: The Mandarin Chinese version of the KDQOL-36™ has been translated by Amgen, Inc. and the MAPI
Institution following the instrument translation specifications provided by the RAND health. The translated
instrument was further reviewed by a Chinese expert panel for content validity and translational equivalence.
The KDQOL-36™ along with Beck depression Inventory-II were administrated to 103 chronic renal disease patients
recruited through convenience sampling procedure from the renal wards and an outpatient dialysis clinic. The
convergent validity was determined through investigating the correlational evidence of the KDQOL-36™ with the
Beck depression Inventory-II and the overall health rating. Known-group validity was supported by the evidence
that the instrument could differentiate subgroups of patients. The internal consistency was estimated using
Cronbach’s α and test-retest reliability was examined using an intraclass correlation coefficient.
Results: For the convergent validity, there were positive correlations between the overall health rating and most
of the KDQOL-36™ subscales, and the Beck depression inventory score was inversely correlated with the mental
component summary score and disease-specific scores of the scale. Significant correlations were noted between
disease-targeted and generic dimensions of the KDQOL-36™. The results of the known-group comparisons indicated
females, the unemployed, and patients had a longer dialysis history reported a worse quality of life. With regard to
the reliability, the Cronbach’s alpha ranged from 0.69 to 0.78, and the intraclass correlation test-retest was higher
than 0.70.
Conclusions: The Mandarin Chinese version of the KDQOL-36™ is a brief, valid, and reliable instrument for use in
examining the quality of life of chronic kidney disease patients in China.Background
Chronic kidney disease (CKD) has become a major global
health issue, affecting around 10-13% of the adult popula-
tion in countries such as the US [1], Taiwan [2], and China
[3]. Owing to the progressive nature of CKD, patients with
CKD are at a high risk of gradually progressing to end
stage renal disease (ESRD). The estimate in current avail-
able reports is that approximately 1.9 million ESRD* Correspondence: susan.chow@polyu.edu.hk
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unless otherwise stated.patients around the world are receiving renal replacement
therapy (RRT); the figure does not capture the proportion
of ESRD patients without access to RRT treatment [4].
Life-long dialysis and kidney transplantation are treatment
choices for patients with ESRD to sustain their lives.
These patients suffer from the signs and symptoms of
relapse, experience fear and anxiety, and face financial
burdens, causing an impaired quality of life [5]. In main-
land China, the number of CKD patients was estimated
to be around 119.5 million based on a national survey in
2010 [3]. Data from the Chinese Renal Data System. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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going haemodialysis (HD), while only 30,000 were
received peritoneal dialysis (PD) treatment at the end of
2012 [6], suggesting that HD is the major treatment
modality in China, accounting for approximately 90% of
the total ESRD patients.
Chronic kidney disease is a progressive disease. Patients
with CKD experienced impaired health-related quality of
life (HRQOL) [7-9], as both the renal disease itself and its
treatment have long-term impacts on lifestyle. Accumulat-
ing studies have generated evidence to support the relation-
ships between impaired HRQOL and clinical outcomes,
such as increased hospitalization and mortality, in CKD
population [10-12]. Attention has recently focused on
effects to improve the HRQOL of persons with CKD.
HRQOL is increasingly being chosen over laboratory data
as the primary outcome measure in clinical research [13]
when examining the effects of treatment, because an
improvement in HRQOL would bring greater fulfillment to
the lives of patients [10]. The routine use of HRQOL mea-
sures creates an opportunity for health care providers to
incorporate the experiences of patients when developing
interventions that best suit their needs given the patients’
adverse life circumstances [14], and to support patient-
centered treatment decisions [15].
The Kidney Disease Quality of Life (KDQOL™) ques-
tionnaire combines the generic SF-36 instrument and
disease-specific components for assessing the HRQOL of
CKD patients. The original questionnaire consists of 134
items, and takes about 30 minutes to complete [16]. The
authors further developed a short version – the KDQOL-
SF™ version 1.3 – which includes 43 items focusing on
kidney disease and SF-36 [17]. The KDQOL-SF™ has been
translated into many languages including Chinese. The
latest abbreviated version – KDQOL-36™ – is even briefer
making it more likely that patients will respond to the
questionnaire [18]. The brief version has also been found
to be suitable for use in routine evaluations of quality of
care in busy practice settings [19] and has been used ex-
tensively to evaluate CKD patients in different stages of
the disease, including patients who are receiving dialysis
treatment [20].
The Mandarin Chinese version of the scale was trans-
lated by Amgen, Inc. and the MAPI Institute and can be
downloaded from the website of the RAND Corporation
[21] for non-commercial use. The translation process
followed the specific guidelines stipulated by the RAND
health [22]. Forward and back forward translations were
adopted to ensure the equivalence between the original
English version of the KDQOL-36™ and the translated
Mandarin Chinese version. The psychometric properties
of the translated version of the scale have not been eval-
uated or reviewed by RAND. Chinese comprise 19% of
the world’s total population. The number of patients inChina with CKD is estimated to be about 119.5 million
[3]. A valid Chinese version of the KDQOL-36™ will
enable researchers to examine the quality of life of CKD
patients within the country and allow for cross-country
comparisons to be made. To address this need, the aim of
the study was to determine the validity and reliability of
the KDQOL-36™ with a Chinese population.
Methods
The study was approved by the Human Subjects Ethical
Sub-committee of the Hong Kong Polytechnic University
and by the hospital in which the study would be conducted.
The participants were informed that their participation
was voluntary and that they could withdraw at any stage.
Sampling and data collection method
One hundred and three patients with mild-to-severe
CKD were recruited from the renal wards and outpatient
dialysis clinics of a tertiary hospital in mainland China
through convenience sampling. This study included both
CKD patients who had commenced dialysis treatment
and those who had not. The criteria for inclusion were
patients who had been diagnosed with CKD, who were
above the age of 18, and who were able to respond to the
questionnaire. The criteria for exclusion were patients
who had been diagnosed with a mental illness. Hobart
et al. suggested that the minimum sample size required
for testing the validity and reliability of an instrument is
80 and 20 subjects, respectively [23]. A sample of 50
subjects or more is required to determine the internal
consistency of a five-point scale [24]. Based on the two
recommendations, the sample size of the study was de-
termined to be no less than 80. The number of subjects
needed to determine the test-retest reliability of the
KDQOL-36™ was estimated using the intraclass correl-
ation coefficient (ICC) value. To achieve a specificity of
0.95 and a power of 0.5, and assuming an ICC value of
0.8 for the instrument with two occasional observations,
a sample size of 22 would suffice to allow for observa-
tions of ICC values of 0.5 or greater [25].
Questionnaires used in the study
The participants completed a self-administered ques-
tionnaire including the KDQOL-36™, Beck Depression
Inventory (BDI-II) and a demographic questionnaire.
Most of the questionnaires were self-administered, with
nurses providing assistance to those patients who were
unable to complete the questionnaires on their own.
The disease-specific core of KDQOL-36™ has 24 items
comprising three scales: Symptoms and Problems (12
items), Burden of Kidney Disease (4 items), and Effects
of Kidney Disease (8 items). The generic core is the 12-
item Short Form Health Survey (SF-12) [26]. The raw
scores are transformed linearly to a range of 0 to 100,
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specific item related to dialysis access was left blank by
patients who were not receiving dialysis. The blank item
was not used to calculate the score, according to the
KDQOL 1.3 Manual for Use and Scoring [17]. The results
of the SF-12 instrument were summarized into the
Physical Component Summary (PCS) score and the
Mental Component Summary (MCS) score. The BDI-II
was used to assess the presence and intensity of depressive
symptoms in clinically depressed or non-depressed
patients. Each item measured via a four-point scale (0–3)
corresponding to a symptom of depression is summed up
to give a single score for the BDI-II [27]. The total score
ranges from 0 to 63, with higher scores indicating severe
depression. The construct validity of the original English
version was supported by the criterion-related validation
and the convergent validation approach [28]. The Mandarin
Chinese version of the BDI-II has good internal consistency
with a Cronbach’s alpha coefficient of 0.94. The construct
validity was supported by the concurrent validity and
exploratory factor analysis approach [29]. A question-
naire on the demographic and clinical information of
the patients was developed by the authors. The items
included questions on age, gender, marital status, educa-
tion level, primary causes of CKD, complications, and
dialysis vintage if the patients were receiving dialysis
treatment.
Validity and reliability testing of the Chinese KDQOL-36™
Validity
Content validity is about whether a scale adequately sam-
ples all possible and relevant questions that exist in terms
of its content [30]. An expert panel that included two aca-
demic researchers, two clinical renal nurses, and a renal
physician was formed to examine the translation equiva-
lence and contents of the instrument. Content validity was
assessed using a four-point Likert scale (1 = ‘not rele-
vant’, 2 = ‘somewhat relevant’, 3 = ‘quite relevant’, 4
= ‘very relevant’) based on the cultural relevance of each
item in measuring HRQOL among CKD patients. Both
the item-level content validity index (CVI) and scale-
level CVI were calculated. The item-level CVI (I-CVI)
was computed as the number of experts giving a rating
of either 3 or 4, divided by the number of experts [31].
The scale-level CVI (S-CVI) was generated as the per-
centage of items on the questionnaire that obtained a
rating of 3 or 4 from all of the reviewers [32].
Convergent validity involves investigating the correl-
ational evidence of a measurement under development
using another scale [30]. The overall health rating and BDI
score were selected to test their correlations with
KDQOL™-36 subscale scores [33]. Previous studies have
shown that depressive symptoms among the CKD popula-
tion are strongly associated with poor health-relatedquality of life in multiple domains [34,35]. We hypothe-
sized that patients with lower subscale scores on the
KDQOL-36™ would report higher levels of depressive
symptoms, as represented by a high BDI-II score. In
addition, the correlation between the overall health rating
and the KDQOL-36™ was examined. The overall health
rating was examined through the first item of the
KDQOL-36™, a global measure of an individual’s HRQOL
[36]. With regard to the impact of the overall health rating
on the HRQOL, previous studies showed that all subscales
of the HRQOL were independently correlated with self-
rated health in the CKD patient group [20]. Based on the
above established evidence, we hypothesized that each
subscale score of the KDQOL-36™ would be positively cor-
related with the overall health rating.
Known-group comparison is an approach used to detect
differences in mean scores between groups that are known
to exhibit different traits on a construct of measurement
[37]. In this study, we compared differences in the scores
of subgroups of patients in terms of demographics and
clinical status, such as age, gender, working status, history
of hospitalization, disease stages and dialysis duration.
Based on previous studies, we assumed that HRQOL
scores would be lower among elderly people, females, the
poorly educated, the unemployed, and people without gov-
ernment health insurance [38-41]. It was also expected that
patients who had been hospitalized during the past six
months and patients who had undergone dialysis for a
longer duration would report lower HRQOL [38]. The cor-
relations between scores on generic and kidney disease-
specific domains were inspected to further establish the
convergent validity. The generic and disease-targeted scales
were hypothesized to be correlated with each other.
Reliability
Reliability pertains to the ability of an instrument to
consistently measure an attribute [42]. In our study, evi-
dence of reliability was derived by examining the
internal consistency and test-retest reliability. Twenty
eight subjects were asked to respond to the same set of
questionnaire within ten to fourteen days interval to de-
termine the stability of the scale.
Acceptability and response burden
Acceptability was assessed by examining the completion
rates and missing data, and identifying the ceiling or floor
effects. The response burden was also evaluated using one
question: ‘Please evaluate the level of difficulty in respond-
ing to this questionnaire’. The available response choices
were ‘easy’, ‘moderate’ and ‘difficult’.
Data analysis
Data analyses were carried out using the SPSS 20.0 (IBM
PASW, USA). All statistical tests were two-tailed and
Table 1 Patients characteristics (n = 103)
Characteristics n (%)
Gender Male 57 (55.3%)
Female 46 (44.8%)
Age, year (Mean, SD) 47.6 (14.2)
Marital status Married 82 (79.6%)
Singled 16 (15.5%)
Divorced/widowed 5 (4.8%)
Education Primary school or below 13 (12.6%)
Secondary school 60 (58.3%)
College or above 30 (29.1%)
Employment status Employed 41 (39.8%)
Unemployed 62 (60.2%)
Health insurance status Government insurance 73 (70.9%)
Self-paying 27 (26.2%)
Other 3 (2.9%)
Primary renal disease Chronic glomerulonephritis 54 (52.4%)
Hypertension 12 (11.7%)
Gouty kidney 10 (9.8%)
Unknown etiology 8 (7.8%)
Diabetes 6 (5.8%)





Haemodialysis (HD) 49 (47.6%)
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centages of patients achieving the highest (100) and lowest
scores (0) were calculated to examine the ceiling and floor
effects of the questionnaire. Descriptive statistics, such as
mean, standard deviation, and percentage, were used to
examine the demographic information. The levels of
skewness and kurtosis were determined to assess the
normality of each variable [43]. Internal consistency
reliability was evaluated using the Cronbach’s alpha
coefficient calculated separately for each subscale. A
coefficient alpha of 0.70 or greater is generally consid-
ered to be acceptable [44]. Test-retest reliability was
estimated by calculating the ICCs based on the two-way
mixed analysis of variance (ICC3,1). An ICC of above
0.75 indicates excellent test-retest reliability, 0.40 and
0.75 are considered to be good, while values of below
0.4 indicate weak agreement [45]. For convergent validity,
Spearman’s correlation coefficients were used to examine
the relationships between subscales of the KDQOL-36™
and the hypothesized measures, as well as correlations be-
tween generic and disease-specific domains. A correlation
of 0.40 is considered substantial for conceptually related
scales [46,47]. Independent t-tests and an analysis of vari-
ance (ANOVA) for continuous variables were used to
evaluate the differences between the hypothesized ‘known’
groups if data were normally distributed.
Results
Characteristics of the study subjects
The mean age of the participants in the study was
47.6 years and more than half were male (55.3%). The ma-
jority were married (79.6%) and not working (60.2%).
With regard to clinical characteristics, chronic glomerulo-
nephritis was the most common cause of CKD (52.4%).
For patients who were receiving dialysis, the mean dur-
ation of treatment was 45.9 months. For details, refer to
Table 1.
Acceptability and descriptive analysis of the scale
The completion rates were high for nearly all of the items
in the KDQOL-36™. None of participants selected ‘diffi-
cult’ for the subjective burden of answering the question-
naire, and 57.3% of the subjects chose ‘moderate’. The
mean scores for each subscale of the KDQOL-36™
ranged from 33.07 to 74.22. Symptoms and problems of
kidney disease had the highest mean score (74.22 ±
15.24) while Burden of kidney disease had the lowest
mean score (33.07 ± 23.31). Regarding the distribution
of the responses to the scales on the KDQOL-36™,
ceiling effects were noted in the Symptom/Problem list
(2.9%) and in the Burden of Kidney disease (1%)
domains. Both the Effect of Kidney Disease (1%) and
Burden of Kidney Disease (13.6%) scales demonstrated
floor effects. The mean BDI-II score was 17.20 (11.43),ranging from 0 to 50. The descriptive statistics of the
KDQOL-36™ are summarized in Table 2.
Validity estimate
For the content validity, the expert panel commented that
the use of ‘bowling’ and ‘playing golf ’ as examples of
‘moderate activities’ in the original Mandarin version were
not appropriate, as these are forms of exercise that
Chinese people do not normally engage in. They were
therefore replaced by ‘Walking’ and ‘Tai Chi’ , which the
Chinese would be more likely to take up for exercise. The
changes were based on the Compendium of Physical
Activities [48,49], which lists the levels of energy expended
in ‘walking’ and practising ‘Tai Chi’ as similar to those for
‘bowling’ and ‘playing golf ’. After the revisions, the panel
determined the content validity using a four-point Likert
scale. The item-level content validity index (I-CVI) and
scale-level CVI (S-CVI) were 1.0.
With regard to convergent validity, significant positive
correlations were found between all of the subscale
scores and the overall health rating score (p < 0.01). Sig-
nificant negative correlations were found between all of
Table 2 Descriptive statistics of the KDQOL-36™
KDQOL-36™ Subscales Mean SD Minimal (Floor%) Maximal (Ceiling%)
Symptoms/problems list 74.22 15.24 37.50 (1) 100 (2.9)
Effects of kidney disease 54.78 20.10 00.00 (1) 96.88 (1)
Burden of kidney disease 33.07 23.31 00.00 (13.6) 100 (1)
Physical Composite Sore 36.60 7.83 17.05 (1) 54.92 (1)
Mental Composite Score 46.82 9.81 22.17 (1) 65.09 (1)
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from 0.395 to 0.654, whilst the correlation coefficient
found between the MCS and BDI scores was higher than
the correlation between the PCS and BDI scores. In
addition, all kidney disease-specific domains were signifi-
cantly correlated with two generic component summaries,
with coefficients ranging from 0.333 to 0.511. The stron-
gest correlation was found between Burden of Kidney
Disease and MCS. No significant correlation was observed
between PCS and MCS. For details, refer to Table 3.
With regard to known-group comparisons, females
and patients who had been hospitalized during the past
6 months had lower scores on the perception of the
Burden of Kidney Disease (P < 0.05), whilst patients who
had been undergoing dialysis for a longer duration re-
ported lower scores on Symptoms and Problems (P < 0.05).
With regard to the generic cores of the KDQOL-36™,
working patients and patients who had undergone dialysis
for a shorter duration had significantly higher PCS scores
(P < 0.05), while patients without government health insur-
ance had significantly lower MCS scores (P < 0.05). Com-
pared to peritoneal dialysis patients and CKD patients who
had not commenced dialysis treatment, haemodialysis
patients had higher PCS and MCS scores (P = 0.036,
P = 0.006, respectively). For details, refer to Table 4.
Reliability estimate
With regard to internal consistency, the Cronbach’s alpha
coefficient for the subscales ranged from 0.69 to 0.78. The
subscale for PCS marginally met the recommended criter-
ion for internal reliability. With regard to test-retestTable 3 Correlations between the domains of the





BDI-II score PCS MCS
Symptoms/
problems list
0.462** −0.506** 0.452** 0.363**
Effects of kidney
disease
0.314** −0.654** 0.329** 0.487**
Burden of kidney
disease
0.447** −0.621** 0.333** 0.511**
PCS 0.499** −0.395** 1 0.152
MCS 0.377** −0.483** 0.152 1
Spearman’s rho correlation, **P < 0.01.reliability, the ICCs ranged from 0.70 to 0.86 for the
subscale scores. For details, refer to Table 5.
Discussion
Mandarin Chinese is spoken by around 850 million people
in China, Taiwan, and Southeast Asia, as well as in the US,
Canada, New Zealand, Peru, and South Africa [50]. This
study is the first validation study of the KDQOL-36™ ques-
tionnaire to have been conducted in China. It has demon-
strated that the Mandarin Chinese version of the scale is
linguistically and culturally relevant to Chinese CKD pa-
tients. The ceiling and floor effects were less than 20%,
suggesting that the instrument can capture the full range
of potential responses in CKD population [51].
Lynn [52] recommended that if five or fewer experts
give a rating, the I-CVI must be 1.0. An S-CVI of 0.8 or
higher is considered acceptable [32]. Both the I-CVI and
S-CVI were 1.0. The results indicated that all items of the
Mandarin Chinese version of KDQOL™-36 were consid-
ered to be appropriate and relevant, giving evidence of the
excellent content validity. During the content validity
process, ‘walking’ and ‘playing Tai Chi’ were used in
place of the problematic examples. Similar amendments
were reported for different versions of the KDQOL-36™,
such as the Korean [53], Filipino [45], Portuguese [54],
and Egyptian [55] versions.
The convergent validity of the KDQOL-36™ was sup-
ported by the hypothesis that those patients who experi-
enced better quality of life had a higher overall health
rating. The overall health rating reflects the individual’s
feelings and provides an estimate of the subjective percep-
tion of one’s health status [33]. Substantial correlations
were observed between overall health and the subscales
for Symptoms and problems, Burden of kidney disease,
and PCS (P < 0.01), confirming that the KDQOL-36™ and
the overall physical health rating are conceptually related.
These results are consistent with studies that have vali-
dated versions of the KDQOL™ instrument in other lan-
guages, such as the Korean [53], Singaporean [56], Greek
[57] and Iranian [51] versions. It was noted that the non-
substantial correlation between the MCS score and the
overall health score could be related to how an individual
perceived his/her overall health. Previous studies have
suggested that amongst the general adult population, the
overall health rating principally reflects the physical
Table 4 Subgroup comparisons of the KDQOL-36™
KDQOL-36™ subscales (Mean, SD)
Symptoms/problems list Burden of kidney disease Effects of kidney disease PCS MCS
Age
Age≤ 45 (n = 46) 73.95 (15.19) 36.55 (24.26) 55.97 (20.61) 36.52 (7.45) 46.35 (9.82)
Age = 46-59 (n = 36) 73.90 (15.92) 31.60 (34.00) 52.59 (20.28) 37.81 (7.81) 45.66 (10.08)
Age≥ 60 (n = 21) 75.34 (14.82) 27.98 (19.53) 55.93 (19.25) 34.72 (8.62) 49.84 (9.11)
P value 0.071 0.341 0.724 0.356 0.275
Gender
Female (n = 46) 72.89 (15.51) 27.04 (21.65) 53.63 (18.09) 36.15 (7.96) 47.26 (9.42)
Male (n = 57) 75.29 (15.07) 37.94 (23.65) 55.71 (21.69) 36.97 (7.77) 46.46 (10.18)
P value 0.431 0.018* 0.604 0.600 0.683
Working status
Working (n = 41) 77.08 (15.36) 55.14 (21.78) 38.72 (24.81) 38.81 (7.95) 45.28 (9.95)
Not working (n = 62) 72.32 (14.98) 54.55 (19.08) 29.33 (21.67) 35.14 (7.45) 47.84 (9.66)
P value 0.121 0.884 0.045 0.019* 0.196
Health insurance
Government paid (n = 73) 74.95 (15.76) 55.25 (19.42) 34.16 (22.29) 36.42 (8.13) 48.33 (9.66)
Self-paid (n = 30) 72.44 (13.97) 53.65 (21.97) 30.42 (25.83) 37.06 (7.13) 43.15 (3.92)
P value 0.452 0.715 0.462 0.709 0.014*
Presence of Complications
Yes (n = 56) 72.79 (15.42) 52.27 (18.51) 29.91 (20.04) 35.22 (7.16) 45.76 (9.72)
No (n = 40) 75.30 (15.44) 57.30 (21.18) 36.72 (27.31) 38.90 (7.45) 47.92 (10.11)
P value 0.434 0.219 0.185 0.017* 0.294
History of hospitalization
Yes (n = 34) 75.54 (13.93) 25.92 (20.65) 53.56 (18.76) 34.80 (7.60) 46.11 (10.37)
No (n = 69) 73.56 (15.90) 36.59 (23.88) 55.38 (20.83) 37.49 (7.84) 47.17 (9.58)
P value 0.539 0.028* 0.667 0.101 0.607
Disease stages
CKD 1–4 (n = 27) 77.10 (14.50) 30.79 (24.75) 55.52 (24.11) 36.71 (8.88) 43.08 (10.38)
PD (n = 27) 69.75 (14.26) 26.39 (18.62) 48.96 (16.22) 33.46 (5.70) 44.84 (7.65)
HD (n = 49) 75.09 (14.50) 38.01 (24.13) 57.58 (19.32) 38.27 (7.84) 49.97 (9.70)
P value 0.179 0.096 0.198 0.036* 0.006*
Dialysis duration
≥60 months (n = 24) 68.06 (15.49) 35.16 (21.87) 54.22 (17.63) 33.99 (8.48) 49.22 (9.99)
<60 months (n = 52) 75.56 (13.60) 33.29 (23.54) 54.66 (19.24) 37.76 (6.73) 47.66 (9.03)
P value 0.036* 0.744 0.926 0.040* 0.501
*P < 0.05. Note: There were missing data for “Presence of Complications”, resulting in the number of patients being less than the total sample size. For “Dialysis
duration”, there were 27 CKD patients were not receiving dialysis; the data were drawn from 76 dialysis patients.
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substantial correlation between the Effects of kidney
disease and the overall health rating. As ESRD patients
were getting used to the idea that they would need life-
long treatment [26], living on dialysis had become their
‘normal way of being’ [59]. To help them to increase their
confidence in maintaining their health, some patients even
considered dialysis to be a ‘part-time job’ [5]. On the other
hand, patients who were receiving dialysis could not avoid
fluid or dietary restrictions even if their condition had im-
proved. Therefore, changes in the patients’ perception oftheir overall health might not have a direct or strong rela-
tionship with the Effects of kidney disease, which is con-
sistent with our results.
The convergent validity of the KDQOL-36™ was also
supported by the hypothesis that patients with lower sub-
scale scores in the KDQOL-36™ would report a higher
BDI-II score. All of the disease-specific domains and the
MCS showed substantial inverse correlations with the BDI
score. Similar findings were reported in previous studies,
showing that depressive symptoms among the CKD popu-
lation were strongly associated with poor health-related
Table 5 Reliability of the KDQOL-36™ subscales
Scales (No. of items) Cronbach’s α (n = 103) ICC (n = 28)
Symptoms/problems list (12) 0.78 0.84
Burden of kidney disease (4) 0.76 0.86
Effects of kidney disease (8) 0.77 0.85
Physical Composite Score (6) 0.69 0.70
Mental Composite Score (6) 0.72 0.81
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correlation was found between the PCS domain and the
BDI score. A possible explanation for this is that our
diverse patient groups experienced different stressors. The
psychological stress of patients who had not yet com-
menced dialysis treatment might not have been related to
impaired physical functioning, but to obligatory hospital
visits or to the fear of becoming dependent on dialysis
[60]. The positive correlations coefficients between the
kidney disease targeted scales and two main composite
summaries from SF-12 demonstrated that the two compo-
nents (generic core and disease-targeted core) of the
KDQOL-36™ are conceptually related. The significant
association presented in this study further supports the
construct validity of the KDQOL-36™, and is in agree-
ment with the results reported in other validation
study [55].
The KDQOL-36™ demonstrated evidence of known-
group validity as the scale scores were able to discrimin-
ate between subgroups of patients. In our study, females,
the unemployed, patients with complications, and pa-
tients who had undergone dialysis for a longer duration
tended to have worse HRQOL. The results corroborated
those of previous studies evaluating the quality of life of
CKD patients, where gender, employment status, comor-
bidities, and dialysis duration were shown to influence
HRQOL scores [39,40,58,61,62]. Contrary to our expecta-
tions, there were no significant differences in any of the
KDQOL-36™ subscale scores among those of different age
groups. A possible explanation for this is that more young
patients were recruited in our study, with only 20.4% of
the participants being older than 60. In addition, the
hypothesis that dialysis patients experience a lower
HRQOL than those who have not yet commenced dialy-
sis was not supported. This could be due to the fact that
the non-dialysis CKD patients recruited in our study
were hospitalized, while the dialysis patients were not.
Hospitalized patients experience a low HRQOL [63].
Hence, the HRQOL of those hospitalized non-dialysis pa-
tients might be lower than that of outpatients who are
receiving dialysis, which is consistent with our findings.
For test-retest reliability, an ICC of 0.70-0.86 demon-
strated the stability of the scale over time [30]. The
Cronbach’s alpha values suggested that the scale is
internally reliable. The internal reliability of all of thesubscales exceeded 0.7, with the PCS (0.69) approaching
the minimum desirable standard. Acceptable levels of
internal consistency suggested that all of the items from
each subscale of the KDQOL-36™ fit together conceptu-
ally and measure the same construct [42].
Conclusions
The results of our present study support the claim that
the Mandarin Chinese version of the KDQOL-36™ is easy
to understand and demonstrates good validity and reliabi-
lity. The evidence supports the view that the questionnaire
is culturally appropriate for use in Chinese populations
with CKD, and can be adopted by both researchers and
health care providers who are interested in understanding
and designing interventions to improve the quality of life
of patients.
There were some limitations to this study. First, the
patients were recruited from a single study site, which
may limit the generalizability of the findings. Second, the
testing was conducted among a mixed sample of CKD
patients with no even distribution according to age. Due
to the limited sample size, this could suggest the existence
of bias, as the younger patients tended to report a higher
HRQOL. The study was conducted using a mixed sample
of CKD patients. Although including a wide range of
patients allowed variations in quality of life measures, it
affected the homogeneity of the sample. A further evalu-
ation of the instrument on a larger Chinese sample is
warranted to support our findings.
Validating an instrument is an ongoing process and
requires a wide and diverse body of evidence [64]. To
accumulate evidence on the construct validity of the
questionnaire, future research is needed to examine the
internal structure of the KDQOL-36™ by exploratory and
confirmatory factor analysis, and to investigate the rela-
tionships of the KDQOL-36™ subscales with other exter-
nal variables using different hypotheses and approaches.
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